Drug Trial Radar · NCT03102723
Platelet Inhibition to Target Reperfusion Injury
Last checked: Nov 20, 2026Latest source record: Apr 26, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
228
Actual
Start
Oct 1, 2017
Primary completion
Dec 2022
Study completion Dec 2022
Sponsor
- Lead sponsor
- National Heart Centre SingaporeAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Tan Tock Seng Hospital; National University Hospital, Singapore; Khoo Teck Puat Hospital; Changi General Hospital; Sengkang General Hospital
- First posted
- Apr 6, 2017
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 21 years, up to 79 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
There remains a clinical need to improve health outcomes in patients with ischemic heart disease (IHD) the leading cause of death and disability in Singapore and worldwide. One neglected therapeutic target is 'myocardial reperfusion injury' in ST-segment elevation myocardial infarction (STEMI) patients treated by primary percutaneous coronary intervention (PPCI). This results in microvascular obstruction (MVO) and cardiomyocyte death and contributes upto 50% of the final myocardial infarct (MI) size. Cangrelor, a potent intravenous platelet P2Y12 inhibitor with rapid onset and offset of action, has been demonstrated in experimental animal studies to reduce MI size when administered prior to reperfusion. Whether Cangrelor given together with Ticagrelor would be more effective at reducing MI size in STEMI patients treated by PPCI is not known and is investigated in the Platelet Inhibition to Target Reperfusion Injury (PITRI) trial.
Conditions
- STEMI
Interventions
CangrelorDrug
1. Cangrelor treatment: IV Cangrelor as a single IV bolus (30 μg/kg) followed by an infusion (4 μg/kg/min) of at least 120 minutes duration or until PPCI procedure has ended (whichever is longer) - this will be initiated prior to PPCI. This dosing regimen is identical to that used in the CHAMPION trials. Or 2. Placebo control: IV normal saline as a single IV bolus followed by an infusion of at least 120 minutes duration or until PPCI procedure has ended (whichever is longer) - this will be initiated prior to PPCI.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Myocardial infarct size by CMR at Day 2 to 7Time frame: 2-7 days
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
National University Hospital (NUH)
Singapore, Singapore
Tan Tock Seng Hospital (TTSH)
Singapore, Singapore
Khoo Teck Puat Hospital
Singapore, Singapore
Changi General Hospital
Singapore, Singapore
SengKang General Hospital
Singapore, Singapore
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.